Telix Net Income From Continuing Ops vs Cost Of Revenue Analysis

TLX Stock

15.76 0.16 1.03%

Telix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Telix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Telix Pharmaceuticals is a good investment. Please check the relationship between Telix Pharmaceuticals Net Income From Continuing Ops and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Telix Pharmaceuticals Net Income From Continuing Ops account and Cost Of Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Telix Pharmaceuticals' Net Income From Continuing Ops and Cost Of Revenue is 0.62. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Telix Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Telix Pharmaceuticals' Net Income From Continuing Ops and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Telix Pharmaceuticals Limited are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income From Continuing Ops i.e., Telix Pharmaceuticals' Net Income From Continuing Ops and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Income From Continuing Ops

Cost Of Revenue

Cost of Revenue is found on Telix Pharmaceuticals income statement and represents the costs associated with goods and services Telix Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Telix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Tax Provision is likely to rise to about (2 M) in 2024. Selling General Administrative is likely to drop to about 57.5 M in 2024

	2021	2023	2024 (projected)
Depreciation And Amortization	236.6K	6.7M	7.1M
Interest Income	1K	1.0M	1.1M

Depreciation And Amortization Interest Income

Telix Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.98	0.81	0.96	0.78	0.97	0.87	-0.74	-0.78	0.93	0.82	0.96	0.97	0.86	0.82	0.95	0.73	0.85	0.85	0.92	0.86	0.88	0.94	0.81	0.96	0.9
Short Long Term Debt Total	0.98		0.79	0.99	0.62	1.0	0.91	-0.64	-0.88	0.98	0.72	0.94	0.99	0.93	0.72	0.99	0.79	0.9	0.93	0.98	0.9	0.89	0.99	0.67	1.0	0.9
Other Current Liab	0.81	0.79		0.82	0.54	0.8	0.92	-0.58	-0.74	0.83	0.5	0.87	0.85	0.82	0.5	0.81	0.57	0.85	0.74	0.73	0.94	0.96	0.81	0.58	0.8	0.83
Total Current Liabilities	0.96	0.99	0.82		0.56	1.0	0.92	-0.56	-0.89	0.99	0.65	0.95	0.99	0.97	0.65	1.0	0.75	0.9	0.94	0.97	0.92	0.9	1.0	0.61	1.0	0.88
Total Stockholder Equity	0.78	0.62	0.54	0.56		0.6	0.47	-0.82	-0.25	0.5	0.89	0.7	0.62	0.37	0.89	0.55	0.37	0.43	0.34	0.5	0.45	0.54	0.51	1.0	0.58	0.61
Property Plant And Equipment Net	0.97	1.0	0.8	1.0	0.6		0.92	-0.62	-0.89	0.98	0.7	0.94	0.99	0.94	0.7	1.0	0.79	0.91	0.94	0.98	0.91	0.9	0.99	0.64	1.0	0.9
Current Deferred Revenue	0.87	0.91	0.92	0.92	0.47	0.92		-0.64	-0.94	0.92	0.59	0.86	0.91	0.9	0.59	0.93	0.82	0.99	0.93	0.91	1.0	0.99	0.93	0.52	0.92	0.95
Net Debt	-0.74	-0.64	-0.58	-0.56	-0.82	-0.62	-0.64		0.5	-0.49	-0.95	-0.57	-0.58	-0.37	-0.95	-0.57	-0.74	-0.67	-0.54	-0.63	-0.61	-0.68	-0.57	-0.82	-0.61	-0.83
Retained Earnings	-0.78	-0.88	-0.74	-0.89	-0.25	-0.89	-0.94	0.5		-0.89	-0.49	-0.74	-0.85	-0.89	-0.49	-0.9	-0.9	-0.97	-0.99	-0.94	-0.93	-0.88	-0.92	-0.3	-0.9	-0.89
Accounts Payable	0.93	0.98	0.83	0.99	0.5	0.98	0.92	-0.49	-0.89		0.56	0.95	0.99	0.99	0.56	0.99	0.7	0.89	0.93	0.94	0.92	0.9	0.99	0.55	0.98	0.84
Cash	0.82	0.72	0.5	0.65	0.89	0.7	0.59	-0.95	-0.49	0.56		0.65	0.66	0.44	1.0	0.65	0.71	0.62	0.57	0.7	0.55	0.62	0.63	0.89	0.69	0.79
Non Current Assets Total	0.96	0.94	0.87	0.95	0.7	0.94	0.86	-0.57	-0.74	0.95	0.65		0.98	0.91	0.65	0.94	0.58	0.8	0.8	0.86	0.87	0.88	0.93	0.74	0.94	0.81
Non Currrent Assets Other	0.97	0.99	0.85	0.99	0.62	0.99	0.91	-0.58	-0.85	0.99	0.66	0.98		0.96	0.66	0.99	0.7	0.88	0.9	0.94	0.91	0.91	0.98	0.66	0.99	0.87
Long Term Debt	0.86	0.93	0.82	0.97	0.37	0.94	0.9	-0.37	-0.89	0.99	0.44	0.91	0.96		0.44	0.97	0.66	0.87	0.92	0.91	0.91	0.87	0.97	0.43	0.95	0.78
Cash And Short Term Investments	0.82	0.72	0.5	0.65	0.89	0.7	0.59	-0.95	-0.49	0.56	1.0	0.65	0.66	0.44		0.65	0.71	0.62	0.57	0.7	0.55	0.62	0.63	0.89	0.69	0.79
Net Receivables	0.95	0.99	0.81	1.0	0.55	1.0	0.93	-0.57	-0.9	0.99	0.65	0.94	0.99	0.97	0.65		0.77	0.91	0.95	0.98	0.92	0.9	1.0	0.6	1.0	0.89
Good Will	0.73	0.79	0.57	0.75	0.37	0.79	0.82	-0.74	-0.9	0.7	0.71	0.58	0.7	0.66	0.71	0.77		0.9	0.9	0.88	0.79	0.77	0.8	0.41	0.79	0.92
Common Stock Shares Outstanding	0.85	0.9	0.85	0.9	0.43	0.91	0.99	-0.67	-0.97	0.89	0.62	0.8	0.88	0.87	0.62	0.91	0.9		0.96	0.93	0.98	0.96	0.92	0.47	0.91	0.97
Non Current Liabilities Total	0.85	0.93	0.74	0.94	0.34	0.94	0.93	-0.54	-0.99	0.93	0.57	0.8	0.9	0.92	0.57	0.95	0.9	0.96		0.98	0.92	0.88	0.96	0.39	0.95	0.9
Capital Lease Obligations	0.92	0.98	0.73	0.97	0.5	0.98	0.91	-0.63	-0.94	0.94	0.7	0.86	0.94	0.91	0.7	0.98	0.88	0.93	0.98		0.9	0.87	0.98	0.55	0.98	0.92
Inventory	0.86	0.9	0.94	0.92	0.45	0.91	1.0	-0.61	-0.93	0.92	0.55	0.87	0.91	0.91	0.55	0.92	0.79	0.98	0.92	0.9		0.99	0.93	0.49	0.91	0.93
Other Current Assets	0.88	0.89	0.96	0.9	0.54	0.9	0.99	-0.68	-0.88	0.9	0.62	0.88	0.91	0.87	0.62	0.9	0.77	0.96	0.88	0.87	0.99		0.91	0.58	0.9	0.94
Total Liab	0.94	0.99	0.81	1.0	0.51	0.99	0.93	-0.57	-0.92	0.99	0.63	0.93	0.98	0.97	0.63	1.0	0.8	0.92	0.96	0.98	0.93	0.91		0.56	1.0	0.89
Net Invested Capital	0.81	0.67	0.58	0.61	1.0	0.64	0.52	-0.82	-0.3	0.55	0.89	0.74	0.66	0.43	0.89	0.6	0.41	0.47	0.39	0.55	0.49	0.58	0.56		0.63	0.65
Property Plant And Equipment Gross	0.96	1.0	0.8	1.0	0.58	1.0	0.92	-0.61	-0.9	0.98	0.69	0.94	0.99	0.95	0.69	1.0	0.79	0.91	0.95	0.98	0.91	0.9	1.0	0.63		0.9
Short Long Term Debt	0.9	0.9	0.83	0.88	0.61	0.9	0.95	-0.83	-0.89	0.84	0.79	0.81	0.87	0.78	0.79	0.89	0.92	0.97	0.9	0.92	0.93	0.94	0.89	0.65	0.9

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Telix Net Income From Continuing Ops vs Cost Of Revenue Analysis

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Cost Of Revenue

Telix Pharmaceuticals fundamental ratios Correlations

Telix Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Telix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 1.0	Total Current Liabilities
Net Receivables	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Total Current Liabilities

Non Current Liabilities Total	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Capital Lease Obligations	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Current Deferred Revenue